MetaCap

Absci (ABSI) vs ICON (ICLR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Absci (ABSI) has outperformed ICON (ICLR) over the past year, gaining 156.3% versus a gain of 13.5%. Over five years, ICLR leads with a -31.4% price change compared with -31.8% for ABSI. ICON is the larger company by market cap ($13.99 billion vs $1.30 billion), about 10.8 times the size.

ICON converts more of its revenue into profit, with a net margin of 2.8% versus -4113.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABSI+156.31%ICLR+13.46%
+331%+131%-70%
Nov 21, 20251 yearNov 20, 2026
ABSI-32.04%ICLR-34.76%
+23%-36%-94%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABSI versus ICLR key metrics
MetricABSIICLR
Share price$7.51$186.71
Market cap$1.30B$13.99B
1-day change-7.97%-1.92%
YTD return+115.19%+2.46%
1-year return+156.31%+13.46%
5-year return-31.79%-31.36%
P/E ratio (TTM)—74.68
Forward P/E—16.09
EPS (TTM)$-0.79$2.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.80M$8.25B
Revenue growth (YoY)-38.24%+0.76%
Net income (latest FY)$-115.18M$229.34M
Gross margin—26.37%
Operating margin-4297.04%5.37%
Net margin-4113.68%2.78%
52-week high$12.55$219.04
52-week low$2.24$66.57
Distance from 52-week high-40.14%-14.76%
Analyst consensusstrong_buybuy
Avg. price target upside+100.93%+23.88%
Average volume4.08M989.87K
Shares outstanding172.75M74.92M
Employees14040,250
SectorHealth CareHealth Care
IndustryBiotechnology: Commercial Physical & Biological ResarchBiotechnology: Commercial Physical & Biological Resarch

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ICON is about 10.8 times larger than Absci by market value ($13.99B vs $1.30B).
  • ABSI has outperformed ICLR by 142.9 percentage points over the past year.
  • ICON is more profitable, keeping 2.8 cents of every revenue dollar as net income versus -4113.7 cents for Absci.
  • ICON grew revenue faster in its latest fiscal year (+0.76% vs -38.24%).

About Absci

ABSI stock →

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.

Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees

About ICON

ICLR stock →

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Health Care · Biotechnology: Commercial Physical & Biological Resarch · 40,250 employees

ABSI vs ICLR FAQ

Which is bigger, Absci or ICON?

ICON (ICLR) is larger, with a market capitalization of $13.99B compared with $1.30B for Absci (ABSI).

Which stock has performed better over the past year, ABSI or ICLR?

ABSI returned +156.31% over the past 12 months, compared with +13.46% for ICLR (price return, excluding dividends). Past performance does not predict future results.

Are Absci and ICON in the same industry?

Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.

More comparisons